MEI Pharma, Inc. - MEIP STOCK NEWS

MEI Pharma, Inc. (NASDAQ: MEIP) announced the grant of inducement stock options for 132,000 shares to four new employees, in line with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.80 per share, equivalent to the stock’s closing price on the grant date. These inducement options are part of the company’s 2021 Inducement Grant Equity Compensation Plan, vesting 25% after one year and the remainder monthly over three years. MEI Pharma focuses on developing cancer therapies, including zandelisib, which is undergoing clinical trials.

MEI Pharma (NASDAQ: MEIP) reported fiscal year 2021 results, concluding on June 30, 2021, showcasing significant developments in their oncology pipeline. Key highlights include advancements in zandelisib, an oral PI3K delta inhibitor, with anticipated topline data from the Phase 2 TIDAL study by year-end. The company reported a net loss of $50.6 million, or $0.45 per share, with cash reserves at $153.4 million. R&D expenses surged to $69.4 million, reflecting costs associated with clinical trials. MEI aims to commercialize zandelisib while expanding its clinical studies.

MEI Pharma, a late-stage pharmaceutical company focused on cancer therapies, will present at two upcoming investor conferences. The first is the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 1:20 p.m. ET. The second presentation will be available for on-demand listening at the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13, 2021, at 7:00 a.m. ET. Interested parties can access these presentations on MEI Pharma's Investors page, along with archived webcasts for 30 days post-event.

MEI Pharma, Inc. (NASDAQ: MEIP) has announced it will release its 2021 fiscal year-end financial results on September 2, 2021, after market close. A conference call to discuss the results and provide a corporate update will be held at 5:00 p.m. ET on the same day. Investors can join the call by dialing 1-833-974-2378 in the U.S. or 1-412-317-5771 internationally. The call will also be accessible via a live webcast on MEI Pharma's investor relations website.

MEI Pharma and Kyowa Kirin announced the dosing of the first patient in the Phase 3 COASTAL study, evaluating zandelisib, a selective PI3Kδ inhibitor, alongside rituximab for relapsed or refractory follicular and marginal zone lymphomas. This study aims to enroll 534 patients and will compare zandelisib plus rituximab to standard chemotherapy. The primary endpoint is progression-free survival, with the results intended to support marketing applications for zandelisib in the U.S. and globally.

MEI Pharma, Inc. (NASDAQ: MEIP) announced the retirement of CFO Brian Drazba, effective end of 2021, after serving since April 2017. Drazba has been pivotal in enhancing the company's financial infrastructure and will support the transitional phase. MEI Pharma is actively searching for a new CFO. The company specializes in developing cancer therapies, with a pipeline that includes four clinical-stage drug candidates, such as zandelisib, currently undergoing multiple trials to gain regulatory approvals.

MEI Pharma, Inc. (NASDAQ: MEIP) has announced the granting of inducement stock options for 306,000 shares to seven new employees, aimed to attract talent. The options, priced at $2.70, match the stock's closing price on the grant date and are part of MEI's 2021 Inducement Grant Equity Compensation Plan. They will vest over a period of time with a term of 10 years. This move aligns with Nasdaq Listing Rule 5635(c)(4), requiring prompt disclosure via press release. The company continues to focus on developing new cancer therapies, with zandelisib undergoing a Phase 2 clinical trial.

MEI Pharma (NASDAQ: MEIP) has appointed Tina C. Beamon, J.D., as chief compliance officer to oversee compliance programs. Beamon brings over 20 years of experience from the healthcare and pharmaceutical sectors, having previously held leadership roles at Karyopharm Therapeutics and Alexion Pharmaceuticals. Her expertise is expected to strengthen MEI's compliance as the company prepares for the commercialization of its lead drug candidate, zandelisib, currently in Phase 2 trials.

MEI Pharma, Inc. (NASDAQ: MEIP) announced the grant of inducement stock options for 169,000 shares to three new employees. The options have an exercise price of $2.85, equal to the stock's closing price on the grant date. Approved by the Compensation Committee, these options vest gradually over ten years. MEI Pharma focuses on developing cancer therapies, with clinical-stage assets like zandelisib. The press release notes potential risks associated with FDA approvals and market acceptance, highlighting the uncertainties of drug development.